David A. Calhoun

Q: What Schools Are Affiliated With David A. Calhoun

David A. Calhoun is affiliated with the following schools: University of Alabama, University of Minnesota, Columbia University, University of Alabama at Birmingham

David A. Calhoun's AcademicInfluence.com Rankings

David A. Calhoun

Philosophy

#6998

World Rank

#10138

Historical Rank

Logic

#4079

World Rank

#5326

Historical Rank

philosophy Degrees

Download Badge

Philosophy

David A. Calhoun's Degrees

Doctorate Medicine University of Virginia
Masters Public Health University of Texas Health Science Center at Houston

Why Is David A. Calhoun Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David A. Calhoun's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). (2002) (5253)
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. (2008) (1933)
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. (2008) (1333)
Hyperaldosteronism Among Black and White Subjects With Resistant Hypertension (2002) (662)
Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension: Results From a Randomized Trial (2009) (483)
Efficacy of low-dose spironolactone in subjects with resistant hypertension. (2003) (469)
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. (2018) (456)
Drugs targeting the renin–angiotensin–aldosterone system (2002) (406)
Mechanisms Responsible for Sympathetic Activation by Cigarette Smoking in Humans (1994) (384)
Pathogenesis of Hypertension (2003) (370)
Plasma Aldosterone is Related to Severity of Obstructive Sleep Apnea in Subjects with Resistant Hypertension but not Subjects with Normal Blood Pressure: 77 (2006) (314)
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide (2007) (295)
Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. (2004) (285)
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. (2008) (280)
Spironolactone Reduces Severity of Obstructive Sleep Apnea in Patients with Resistant Hypertension: a Preliminary Report (2009) (263)
Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. (2004) (249)
Sleep and hypertension. (2010) (240)
Resistant hypertension: incidence, prevalence, and prognosis. (2012) (205)
Apparent and true resistant hypertension: definition, prevalence and outcomes (2014) (192)
Physical training and baroreceptor control of sympathetic nerve activity in humans. (1994) (190)
Refractory Hypertension: Definition, Prevalence, and Patient Characteristics (2012) (187)
Impaired Endothelium-Dependent Flow-Mediated Vasodilation in Hypertensive Subjects With Hyperaldosteronism (2004) (182)
Triple Antihypertensive Therapy With Amlodipine, Valsartan, and Hydrochlorothiazide: A Randomized Clinical Trial (2009) (182)
Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial (2011) (174)
Refractory Hypertension: Determination of Prevalence, Risk Factors, and Comorbidities in a Large, Population-Based Cohort (2014) (172)
Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. (2013) (169)
The National Health and Nutrition Examination Survey III (2001) (163)
Obstructive sleep apnea, hypertension and cardiovascular diseases (2015) (162)
Treatment of hypertensive crisis. (1990) (161)
Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. (2010) (154)
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease: Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (150)
Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. (2005) (146)
The Unrecognized Prevalence of Primary Aldosteronism (2020) (144)
Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients With Resistant Hypertension and Hyperaldosteronism: A Prospective Clinical Study (2010) (144)
Obstructive Sleep Apnea and Hypertension (2010) (143)
Management of hypertension in CKD: beyond the guidelines. (2015) (141)
Resistant hypertension, obstructive sleep apnoea and aldosterone (2012) (136)
Prevalence of Optimal Treatment Regimens in Patients With Apparent Treatment-Resistant Hypertension Based on Office Blood Pressure in a Community-Based Practice Network (2013) (136)
Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and non-resistant hypertension (2015) (136)
Normotensive blacks have heightened sympathetic response to cold pressor test. (1993) (130)
Prevalence of apparent treatment-resistant hypertension among individuals with CKD. (2013) (122)
Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. (2008) (114)
Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. (2014) (110)
Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus (2014) (110)
Diurnal blood pressure variation and dietary salt in spontaneously hypertensive rats. (1994) (96)
Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. (2003) (93)
Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension (2002) (93)
Prevalence of Apparent Treatment-Resistant Hypertension in the United States: Comparison of the 2008 and 2018 American Heart Association Scientific Statements on Resistant Hypertension (2019) (92)
Hyperaldosteronism as a common cause of resistant hypertension. (2013) (87)
Racial differences in abnormal ambulatory blood pressure monitoring measures: Results from the Coronary Artery Risk Development in Young Adults (CARDIA) study. (2015) (84)
Sleep, insomnia, and hypertension: current findings and future directions. (2017) (83)
Prevalence and Correlates of Low Medication Adherence in Apparent Treatment‐Resistant Hypertension (2012) (80)
Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement (2017) (78)
Lancet Commission on Hypertension group position statement on the global improvement of accuracy standards for devices that measure blood pressure (2019) (78)
Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension (2008) (77)
Refractory Hypertension: Evidence of Heightened Sympathetic Activity as a Cause of Antihypertensive Treatment Failure. (2015) (77)
Efficacy and safety of initial combination therapy with amlodipine/valsartan compared with amlodipine monotherapy in black patients with stage 2 hypertension: the EX-STAND study (2009) (72)
Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness (2011) (72)
Clinical Significance of Incident Hypokalemia and Hyperkalemia in Treated Hypertensive Patients in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2012) (72)
Relation of torsion and myocardial strains to LV ejection fraction in hypertension. (2012) (71)
Aldosterone Blockers (Mineralocorticoid Receptor Antagonism) and Potassium‐Sparing Diuretics (2011) (70)
Geographic and Demographic Variability in 20-Year Hypertension Incidence: The CARDIA Study (2011) (67)
Cumulative Incidence of Hypertension by 55 Years of Age in Blacks and Whites: The CARDIA Study (2018) (66)
Treatment of Resistant and Refractory Hypertension. (2019) (65)
Primary Aldosteronism: Diagnosis and Treatment (2006) (65)
Sleep apnea, aldosterone, and resistant hypertension. (2009) (60)
Blood pressure and treatment of persons with hypertension as it relates to cognitive outcomes including executive function. (2012) (60)
Resistant hypertension, secondary hypertension, and hypertensive crises: diagnostic evaluation and treatment. (2010) (58)
The role of aldosteronism in causing obesity-related cardiovascular risk. (2010) (58)
Aldosteronism and hypertension. (2006) (57)
Managing the patient with hard-to-control hypertension. (1998) (56)
Healthy Lifestyle Factors and Risk of Cardiovascular Events and Mortality in Treatment-Resistant Hypertension: The Reasons for Geographic and Racial Differences in Stroke Study (2014) (56)
Is there an unrecognized epidemic of primary aldosteronism? Pro. (2007) (55)
The New ACC/AHA Hypertension Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. (2018) (55)
Detection, evaluation, and treatment of severe and resistant hypertension: proceedings from an American Society of Hypertension Interactive forum held in Bethesda, MD, U.S.A., October 10th 2013. (2014) (55)
Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. (2005) (54)
Resistant hypertension and aldosterone: an update. (2012) (53)
A dual propagation contours technique for semi-automated assessment of systolic and diastolic cardiac function by CMR (2009) (53)
Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. (2013) (52)
Gender and dietary NaCl in spontaneously hypertensive and Wistar-Kyoto rats. (1995) (52)
Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. (2016) (52)
Cigarette smoking and the adrenergic nervous system. (1992) (51)
Resistant hypertension and aldosteronism (2007) (51)
Positive relationship of sleep apnea to hyperaldosteronism in an ethnically diverse population (2011) (50)
Resistant or Difficult‐to‐Treat Hypertension (2006) (50)
Aldosterone and cardiovascular disease: smoke and fire. (2006) (49)
Non-dipping pattern relates to endothelial dysfunction in patients with uncontrolled resistant hypertension (2011) (49)
Low‐Dose Aldosterone Blockade as a New Treatment Paradigm for Controlling Resistant Hypertension (2007) (49)
Thrombopoietin (Tpo) in the fetus and neonate: Tpo concentrations in preterm and term neonates, and organ distribution of Tpo and its receptor (c-mpl) during human fetal development. (1999) (49)
Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure (2016) (48)
Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial. (2001) (48)
The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study (2013) (47)
Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease (2012) (46)
Incident ESRD and treatment-resistant hypertension: the reasons for geographic and racial differences in stroke (REGARDS) study. (2014) (46)
Preventing increases in early-morning blood pressure, heart rate, and the rate-pressure product with controlled onset extended release verapamil at bedtime versus enalapril, losartan, and placebo on arising. (2002) (44)
Hypertension in blacks: socioeconomic stress and sympathetic nervous system activity. (1992) (44)
Prevalence and Clinical Characteristics of Refractory Hypertension (2017) (43)
Characterization and treatment of resistant hypertension (2009) (43)
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension (2011) (42)
Aldosteronism and Resistant Hypertension (2011) (42)
Aldosterone receptor antagonists: current perspectives and therapies (2013) (41)
Treatment of resistant hypertension. (2010) (40)
Marked Regional Left Ventricular Heterogeneity in Hypertensive Left Ventricular Hypertrophy Patients: A Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Cardiovascular Magnetic Resonance and Echocardiographic Substudy (2008) (40)
Race, family history of hypertension, and sympathetic response to cold pressor testing. (1997) (40)
Amlodipine/valsartan/hydrochlorothiazide triple combination therapy in moderate/severe hypertension: Secondary analyses evaluating efficacy and safety (2009) (39)
Use of aldosterone antagonists in resistant hypertension. (2006) (38)
Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension (2016) (38)
Racial differences in the pathogenesis of hypertension. (1995) (38)
Physical exercise in essential hypertension. (1992) (38)
Use of Aldosterone Antagonists for Treatment of Uncontrolled Resistant Hypertension (2017) (38)
Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal DiseaseNovelty and Significance (2014) (37)
Aldosterone excess and resistance to 24-h blood pressure control (2007) (37)
First Brazilian position on resistant hypertension. (2012) (37)
Resistant and Refractory Hypertension: Antihypertensive Treatment Resistance vs Treatment Failure. (2016) (36)
Management of patients with resistant hypertension: current treatment options (2013) (36)
Resistant hypertension and hyperaldosteronism (2008) (34)
Aldosterone and cardiovascular disease. (2009) (34)
Refractory versus resistant hypertension: Novel distinctive phenotypes. (2017) (34)
Moderate waist circumference and hypertension prevalence: the REGARDS Study. (2011) (33)
Evaluation of Low-dose Endotoxin Administration during Pregnancy as a Model of Preeclampsia (2000) (33)
Resistant Hypertension: An Update of Experimental and Clinical Findings. (2017) (33)
Use of Aldosterone Antagonists in Resistant Hypertension (2004) (33)
Gene variation in resistant hypertension: multilocus analysis of the angiotensin 1-converting enzyme, angiotensinogen, and endothelial nitric oxide synthase genes. (2011) (32)
OR-46: High prevalence of primary aldosteronism among black and white subjects with resistant hypertension (2002) (31)
SPRINT Proves that Lower Is Better for Nondiabetic High-Risk Patients, but at a Price. (2016) (31)
Treatment of primary aldosteronism is associated with a reduction in the severity of obstructive sleep apnoea (2017) (31)
High NaCl Diet Enhances Arterial Baroreceptor Reflex in NaCl‐Sensitive Spontaneously Hypertensive Rats (1991) (30)
Association of filtered sodium load with medullary volumes and medullary hypoxia in hypertensive African Americans as compared with whites. (2012) (29)
Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy (2014) (29)
The role of aldosterone antagonists in the management of resistant hypertension (2005) (29)
Association Between Sleep Apnea and Blood Pressure Control Among Blacks: Jackson Heart Sleep Study (2019) (28)
Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. (2012) (28)
Muscle sympathetic nervous system activity in Black and Caucasian hypertensive subjects (1994) (27)
Associations between Vascular Health Indices and Serum Total, Free and Bioavailable 25-Hydroxyvitamin D in Adolescents (2014) (27)
Apparent Treatment-resistant Hypertension Among Individuals with History of Stroke or Transient Ischemic Attack. (2015) (27)
Improving Blood Pressure Control: Increase the Dose of Diuretic or Switch to a Fixed‐Dose Angiotensin Receptor Blocker/Diuretic? The Valsartan Hydrochlorothiazide Diuretic for Initial Control and Titration to Achieve Optimal Therapeutic Effect (Val‐DICTATE) Trial (2008) (26)
Clinic and ambulatory blood pressure in a population-based sample of African Americans: the Jackson Heart Study. (2017) (26)
Apparent and true resistant hypertension: why not the same? (2013) (25)
Effect of continuous positive airway pressure in patients with true refractory hypertension and sleep apnea: a post-hoc intention-to-treat analysis of the HIPARCO randomized clinical trial (2019) (25)
Out-of-Clinic Sympathetic Activity Is Increased in Patients With Masked Uncontrolled Hypertension (2019) (25)
Hypertensive crisis since FDR--a partial victory. (1995) (25)
Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. (2001) (24)
Refractory Hypertension Is not Attributable to Intravascular Fluid Retention as Determined by Intracardiac Volumes (2018) (24)
Increased Circulating Inflammatory Endothelial Cells in Blacks With Essential Hypertension (2013) (24)
Prevalence of refractory hypertension in the United States from 1999 to 2014. (2019) (23)
Treatment resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (2014) (23)
White-Coat Effect Is Uncommon in Patients With Refractory Hypertension (2017) (22)
The role of aldosterone in resistant hypertension: Implications for pathogenesis and therapy (2007) (22)
Refractory HypertensionNovelty and Significance (2015) (21)
Interaction between lifetime captopril treatment and NaCI-sensitive hypertension in spontaneously hypertensive rats and Wistar-Kyoto rats. (1999) (21)
The calcium antagonists in the 1990s. An overview. (1991) (21)
Refractory versus resistant hypertension (2017) (20)
Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number (2017) (20)
Aldosterone, dietary salt, and renal disease. (2006) (19)
Association of Sleep Characteristics With Nocturnal Hypertension and Nondipping Blood Pressure in the CARDIA Study (2020) (19)
Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension (2008) (19)
Nocturnal Blood Pressure in Young Adults and Cognitive Function in Midlife: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. (2015) (19)
Blood pressure monitoring in sleep: time to wake up. (2019) (19)
Aldosterone and metabolic dysfunction: an unresolved issue. (2009) (18)
Unresolved Issue (2020) (18)
Resistant hypertension: bad and getting worse. (2011) (18)
Attitudes about and psychosocial outcomes of HFE genotyping for hemochromatosis. (2004) (18)
Associations of C-Reactive Protein to Indices of Vascular Health and the Influence of Serum 25(OH)D Status in Healthy Adults (2012) (18)
Hypertension and orthostatic hypotension in older patients. (2012) (17)
Salt and aldosterone: a concert of bad effects. (2010) (17)
A practical approach for measurement of antihypertensive medication adherence in patients with resistant hypertension. (2016) (16)
Stroke outcomes among participants randomized to chlorthalidone, amlodipine or lisinopril in ALLHAT. (2014) (16)
Contemporary management of refractory hypertension (1999) (16)
Effect of Serum Urate Lowering With Allopurinol on Blood Pressure in Young Adults: A Randomized, Controlled, Crossover Trial (2021) (16)
TREATMENT RESISTANT HYPERTENSION IN A COMMUNITY-BASED PRACTICE NETWORK (2013) (16)
Do We Need a New Definition of Hypertension After SPRINT? (2016) (15)
High blood pressure in women. (1997) (15)
Effects of demographics on the antihypertensive efficacy of triple therapy with amlodipine, valsartan, and hydrochlorothiazide for moderate to severe hypertension (2013) (15)
Refractory and Resistant Hypertension: Antihypertensive Treatment Failure versus Treatment Resistance (2016) (15)
Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. (2018) (15)
Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status (2016) (15)
Etiology and pathogenesis of systemic hypertension (2009) (14)
Serum 25-hydroxyvitamin D and Ethnic Differences in Arterial Stiffness and Endothelial Function (2012) (14)
Excitatory sympathetic reflex in NaCl-sensitive spontaneously hypertensive rats. (1993) (14)
Factors associated with the changes from a resistant to a refractory phenotype in hypertensive patients: a Pragmatic Longitudinal Study (2019) (14)
ASH Scientific Statement Detection, evaluation, and treatment of severe and resistant hypertension Proceedings from an American Society of Hypertension Interactive Forum held in Bethesda, MD, USA, October 10th 2013 (2014) (14)
Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function (2014) (14)
Antihypertensive Medication Adherence and Confirmation of True Refractory Hypertension (2019) (14)
Comparisons of sleep apnoea rate and outcomes among patients with resistant and non‐resistant hypertension (2016) (13)
Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension (2014) (13)
Use of single-pill combination therapy in the evolving paradigm of hypertension management (2009) (13)
Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. (2017) (13)
Masked Uncontrolled Hypertension Is Not Attributable to Medication Nonadherence. (2019) (13)
Resistant hypertension (2002) (13)
Reserpine Substantially Lowers Blood Pressure in Patients with Refractory Hypertension: A Proof of Concept Study. (2020) (12)
Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. (2014) (12)
Plasma xanthine oxidase activity is related to increased sodium and left ventricular hypertrophy in resistant hypertension. (2019) (12)
Atrial natriuretic peptide blunts arterial baroreflex in spontaneously hypertensive rats. (1996) (12)
Atrial natriuretic peptide modulates baroreceptor reflex in spontaneously hypertensive rat. (1992) (12)
Recent Advancements in the Treatment of Resistant Hypertension (2012) (12)
The association of nocturnal hypertension and nondipping blood pressure with treatment‐resistant hypertension: The Jackson Heart Study (2018) (11)
Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance (2014) (11)
Monitoring of sympathetic activity in man: physiology and pharmacology. (1992) (11)
Aldosterone antagonism: An emerging strategy for effective blood pressure lowering (2005) (11)
Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant (2017) (11)
Resistant Hypertension Management: Comparison of the 2017 American and 2018 European High Blood Pressure Guidelines (2019) (10)
BLOCKADE OF ALDOSTERONE PRODUCTION AS A NOVEL APPROACH TO THE MANAGEMENT OF HIGH BLOOD PRESSURE: EFFICACY AND TOLERABILITY OF THE ALDOSTERONE SYNTHASE INHIBITOR LCI699 IN PATIENTS WITH STAGE 1-2 HYPERTENSION (2010) (9)
Effects of 4 weeks of amlodipine therapy on muscle sympathetic nerve activity (1997) (9)
Role of Mineralocorticoid Receptors in Obstructive Sleep Apnea and Metabolic Syndrome (2018) (9)
Pretreatment with enalaprilat blunts nicardipine-induced sympathetic activation in spontaneously hypertensive and Wistar-Kyoto rats. (1999) (9)
Predictors of silent myocardial ischemia in resistant hypertensive patients. (2015) (9)
Weight gain and hypertension: the chicken-egg question revisited. (2004) (9)
Hypertension and Sympathetic Nervous System Activity (2004) (8)
Resistant hypertension: who and how to evaluate (2009) (8)
Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension (2006) (8)
Treatment of resistant hypertension. (2009) (8)
2008 American Heart Association Statement on diagnosis, evaluation, and treatment of resistant hypertension: what should we remember in everyday practice? (2008) (8)
Sleep disorders and hypertension risk (2017) (8)
BP Targets in Hypertension: What Should We Do Now That SPRINT Is Out? (2016) (8)
Masked Uncontrolled Hypertension Is Accompanied by Increased Out-of-Clinic Aldosterone Secretion. (2020) (8)
Management of Resistant Hypertension: Do Not Give Up on Medication. (2014) (8)
Alterations in sympathetic nerve traffic during cigarette-smoking in man: a preliminary report. (1991) (8)
Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension? (2016) (7)
True versus pseudoresistant hypertension. (2017) (7)
Medical Versus Surgical Treatment of Primary Aldosteronism. (2018) (7)
Introduction to the American Heart Association's Hypertension Strategically Focused Research Network. (2016) (7)
Fluid retention, aldosterone excess, and treatment of resistant hypertension. (2018) (7)
Effectiveness of initiating treatment with valsartan/hydrochlorothiazide in patients with stage-1 or stage-2 hypertension (2009) (7)
Current options for the treatment of resistant hypertension (2009) (7)
Enalaprilat blunts reflexive increases in cardiac interstitial norepinephrine in conscious rats (2001) (7)
Assessment of vascular function in low socioeconomic status preschool children: a pilot study. (2017) (7)
Spironolactone Reduces Aortic Stiffness in Patients With Resistant Hypertension Independent of Blood Pressure Change. (2021) (7)
Underutilization of Treatment for Black Adults With Apparent Treatment-Resistant Hypertension (2020) (6)
Primary aldosteronism: Diagnostic and therapeutic considerations (2005) (6)
Resistant Hypertension: An Update. (2018) (6)
Renal Nerve Denervation, Adherence, and Management of Resistant Hypertension (2016) (6)
The effects of urate lowering therapy on inflammation, endothelial function, and blood pressure (SURPHER) study design and rationale. (2016) (6)
Association of Obstructive Sleep Apnea with Nighttime Blood Pressure in African Americans: the Jackson Heart Study. (2020) (5)
Paradoxical increase of 24-hour urinary aldosterone levels in obese patients with resistant hypertension on a high salt diet. (2020) (5)
Effects of dietary sodium reduction on blood pressure in patients with resistant hypertension (2010) (5)
Reduction of blood pressure in patients with treatment-resistant hypertension (2009) (5)
11-Beta Dehydrogenase Type 2 Activity Is Not Reduced in Treatment Resistant Hypertension (2017) (5)
National patterns in intensity and frequency of outpatient care for apparent treatment‐resistant hypertension (2017) (5)
Racial Differences in Maintaining Optimal Health Behaviors Into Middle Age. (2019) (5)
Advances in resistant hypertension. (2018) (5)
Uric Acid Is Not Associated with Blood Pressure Phenotypes and Target Organ Damage According to Blood Pressure Phenotypes. (2020) (5)
Chapter 3 – Pathophysiology of Hypertension (2007) (4)
True resistant hypertension: definition and prevalence. (2012) (4)
Antihypertensive Medications and Falls in the Elderly. (2018) (4)
Cardiovascular risk of systolic versus diastolic blood pressure in Western and non-Western countries. (2006) (4)
Chapter 2 – Pathogenesis of Hypertension (2013) (4)
Regional Heterogeneity in 3D Myocardial Shortening in Hypertensive Left Ventricular Hypertrophy: A Cardiovascular CMR Tagging Substudy to the Life Study (2015) (4)
Apparent treatment-resistant hypertension: characteristics and prevalence in a real-world environment of an integrated health system. (2020) (4)
Sympathetic-vascular interactions: further evidence in kidney transplantation. (2002) (4)
LOW PREVALENCE OF WHITE-COAT HYPERTENSION IN SUBJECTS WITH RESISTANT HYPERTENSION AND HYPERALDOSTERONISM: P 772 (2004) (3)
Spironolactone improves blood pressure and left ventricular hypertrophy in patients with resistant hypertension (2007) (3)
Characterizing Workers Participating in a Worksite Wellness Health Screening Program Using Blood Pressure Control, Self-Monitoring, Medication Adherence, Depression, and Exercise (2014) (3)
Hypertensive crisis: forget the numbers. (2012) (3)
Patient Characteristics Associated With Resistant Hypertension Older age High baseline blood pressure Obesity Excessive dietary salt ingestion Chronic kidney disease Diabetes Left ventricular hypertrophy Black race Female sex (2008) (2)
Characterizing workers participating in a worksite wellness health screening program using blood pressure control, self-monitoring, medication adherence, depression, and exercise. (2014) (2)
Sympathetic Activity, Hypertension, and The Importance of a Good Night's Sleep. (2016) (2)
A16 – Sexual dimorphism in NaCl sensitivity of blood pressure in the spontaneously hypertensive rat (1995) (2)
An Update on Refractory Hypertension (2022) (2)
Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk. (2016) (2)
Activation by Cigarette Smoking in Humans (2005) (2)
Blood Pressure Measurement Challenges in Severely Obese Patients. (2018) (2)
Clinical Trials Report (2005) (2)
TREATMENT OF HYPERTENSIVE CRISIS. AUTHORS' REPLY (1991) (2)
SY 14-3 PRIMARY ALDOSTERONISM IN RESISTANT HYPERTENSION. (2016) (2)
Obstructive sleep apnea is more severe in men but not women with refractory hypertension compared with controlled resistant hypertension (2020) (2)
Spironolactone versus renal nerve denervation for treatment of uncontrolled resistant hypertension. (2016) (2)
Case of Episodic and Positional Hypertension: Diagnosis and Treatment. (2020) (1)
Prevalence of pseudoresistant hypertension due to blood pressure measurement technique in a hypertension specialty clinic (2016) (1)
UNCONTROLLED AND CONTROLLED RESISTANT HYPERTENSION: REALLY ONLY ONE HYPERTENSIVE CONDITION?: PP.34.412 (2010) (1)
A013: Pre-treatment with irbesartan blunts nicardipine-induced increase in sympathetic activation (2000) (1)
SY 14-3 PRIMARY ALDOSTERONISM IN RESISTANT HYPERTENSION. (2016) (1)
4P-1039 Rosuvastatin-induced modulation of NO-dependent superoxide formation (2003) (1)
Editorial Commentary Resistant Hypertension Bad and Getting Worse (2011) (1)
Abstract P369: Non-Adherence to Antihypertensive Medications is Associated with Higher BP and Anxiety Levels. (2018) (1)
Anxiety and sleep as potential mechanisms underlying heightened sympathetic tone in patients with refractory hypertension (2016) (1)
Apparent resistant hypertension and medication adherence (2011) (1)
P-345: High prevalence of obstructive sleep apnea among hypertensive patients with primary hyperaldosteronism (2003) (1)
OP0208 EFFECT OF SERUM URATE LOWERING WITH ALLOPURINOL ON BLOOD PRESSURE IN YOUNG ADULTS (2019) (1)
O-59: Preventing early-morning blood pressure and rate-pressure product excesses in patients with hypertension (2001) (1)
Fenoldopam: A novel, peripherally acting dopamine-1 agonist for parenteral treatment of hypertension (1997) (1)
for High Blood Pressure Research From the American Heart Association Professional Education Committee of the Council Resistant Hypertension: Diagnosis, Evaluation, and Treatment : A Scientific Statement (2013) (1)
Abstract 20887: Masked Uncontrolled Hypertension is Not Attributable to Medication Non-Adherence (2017) (1)
Response to Hyperaldosteronism and Left Ventricular Hypertrophy (2010) (1)
Hyperaldosteronism causes volume overload cardiac hypertrophy in patients with resistant hypertension (2008) (1)
RAPID IMPROVEMENT IN AORTIC DISTENSIBILITY AND PULSATILITY WITH SPIRONOLACTONE THERAPY IN PATIENTS WITH RESISTANT HYPERTENSION: A CARDIAC MRI STUDY (2011) (1)
Abstract 964: Effect of Volume Overload on Left Ventricular Torsion and Extra Cellular Matrix (2007) (1)
High blood pressure in older adults: a conversation with Dr David Calhoun. (2007) (1)
P-623: Low sodium diet protects from aldosterone-induced endothelial dysfucntion and left ventricular hypertrophy in subjects with resistant hypertension (2005) (1)
Effects of Spironolactone and Renal Denervation Treatment on Blood Pressure and Its Variability-Different Aspects of Hypertension Treatment. (2017) (1)
Aortic blood pressure and arterial stiffness in patients with controlled resistant and non‐resistant hypertension (2020) (1)
Results of an Academic, Health Care Worksite Weight Loss Contest for Southeastern Americans (2015) (1)
A Message From the New Editorial Team at the American Journal of Hypertension. (2016) (1)
Characteristics of young and old patients with resistant hypertension in a large, diverse cohort (2015) (1)
Progesterone does not prevent ovariectomy induced NaCl-sensitivity in female spontaneously hypertensive rats. (1996) (1)
Abstract 66: Increased Circulating Inflammatory Endothelial Cells (IEC) in African-American vs. Caucasians with Essential Hypertension (2012) (0)
Resistant Hypertension (2002) (0)
Research Article Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension (2008) (0)
Abstract 3292: Torsional Deformation Compensates for Depressed Systolic Myocardial Strains in Hypertensive Concentric Left Ventricular Hypertrophy (2009) (0)
Abstract 92: Prevalence and Predictors of Apparent Treatment-Resistant Hypertension among Individuals with a History of Physician-Diagnosed Stroke or TIA (2014) (0)
Research Article Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality (2014) (0)
1052 Continuous Blood Pressure Monitoring In Sleep (2020) (0)
Abstract 204: Non-dipper Pattern Is Associated With Urinary Metanephrines In Patients With Refractory Hypertension (2014) (0)
Evaluation and treatment of resistant hypertension (2007) (0)
HIGH DIETARY SODIUM BLUNTS EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISM ON LEFT VENTRICULAR HYPERTROPHY IN RESISTANT HYPERTENSION PATIENTS (2016) (0)
Abstract 4853: Spironolactone Therapy is Associated With Rapid Improvements in Blood Pressure Control and Cardiac Remodeling in Patients With Resistant Hypertension (2009) (0)
Abstract P048: The Association Between Apparent Treatment Resistant Hypertension and Low Mental and Physical Functioning, Depressive Symptoms, and Stress. (2014) (0)
Abstract 15838: Oxidative Stress is Related to Increased Sodium-Aldosterone Product and Left Ventricular Dysfunction in Resistant Hypertension (2017) (0)
OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX (2016) (0)
1059 POLYSOMNOGRAPHIC CHARACTERISTICS OF PATIENTS WITH REFRACTORY HYPERTENSION COMPARED TO CONTROLLED RESISTANT HYPERTENSION (2017) (0)
Racial Differences in XO (Xanthine Oxidase) and Mitochondrial DNA Damage-Associated Molecular Patterns in Resistant Hypertension (2022) (0)
Abstract 64: Heart Rate Values and Variability in Controlled versus Resistant Hypertensive Patients and in True versus False Resistant Hypertensives (2013) (0)
High-salt diet and aldosterone induces vascular damage and fluid retention in patients with resistant hypertension (2008) (0)
Response to Letter to Regarding Article, “Effects of Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension: Results of a Randomized, Double-Blind, Placebo- and Active-Controlled Phase 2 Trial” (2012) (0)
P-235: Verapamil, diltiazem, and nicardipine have similar acute sympathetic activation (2001) (0)
Resistant and refractory hypertension : Antihypertensive treatment resistance versus treatment failure Short title : Resistant and refractory hypertension (2015) (0)
Chapter 31 – Resistant Hypertension (2013) (0)
Abstract 2583: Dietary Salt Modulates the Hypertensive Effect of High Aldosterone in Subjects with Resistant Hypertension (2006) (0)
244 GENDER DIFFERENCE IN ALDOSTERONE EXCRETION IN SUBJECTS WITH RESISTANT HYPERTENSION. (2006) (0)
Abstract P251: Out-of-clinic Cortisol Secretion Is Increased In Masked Uncontrolled Hypertension (2021) (0)
Diastolic function: modeling left ventricular untwisting as a damped harmonic oscillator (2022) (0)
Abstract 114: Sympathetic Activity Increases With Obesity in Hypertensive Patients (2017) (0)
Paradoxical effect of age on improvements in pulse pressure during blood pressure lowering (2015) (0)
Abstract 15862: Epidemiology and Outcomes of Resistant Hypertension in 5788 Community-Dwelling Older Adults (2011) (0)
IMPAIRED FLOW-MEDIATED VASODILATION SECONDARY TO CHRONIC ALDOSTERONE EXCESS: P 770 (2004) (0)
Case of Refractory Hypertension Controlled After Aortic and Mitral Valve Replacement and Coronary Artery Bypass Grafting. (2018) (0)
Abstract 2464: Severity of Obstructive Sleep Apnea Dependent upon Aldosterone Status in Subjects with Resistant Hypertension (2008) (0)
Abstract MP69: Prevalence of Treatment Resistant Hypertension Among Individuals with Chronic Kidney Disease: Results from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study (2013) (0)
OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN. (2016) (0)
Assessment of vascular function in normotensive and hypertensive preschool children: A pilot study (2016) (0)
High dietary salt worsens aldosterone-induced proteinuria in patients with resistant hypertension (2007) (0)
The predictors of pulse pressure independent of systolic blood pressure in resistant hypertension (2015) (0)
Left ventricular torsional hysteresis in patients with hypertension: a global parameter for diastolic function (2013) (0)
235: Effects of Aldosterone Receptor Blockers in Resistant Hypertension and Stage III Chronic Kidney Disease (2010) (0)
SPIRONOLACTONE DOES NOT CHANGE 24HR BP CIRCADIAN PATTERN IN RESISTANT HYPERTENSIVE PATIENTS (2019) (0)
Abstract 4428: Similar Response to Spironolactone in Whites and African American Patients with Resistant Hypertension (2008) (0)
Response to About an Epidemic of Primary Aldosteronism (2008) (0)
Is There an Epidemic of Primary Aldosteronism ? ( Pro ) (2007) (0)
Abstract 3004: Assessment of Left Atrial Volume in Resistant Hypertension by Cardiac Magnetic Resonance Imaging (2006) (0)
57 OBSTRUCTIVE SLEEP APNEA IS PREVALENT IN PRIMARY ALDOSTERONISM: 3D MAGNETIC RESONANCE IMAGING TO STUDY IMPROVEMENT WITH ALDOSTERONE BLOCKADE - PRELIMINARY FINDINGS (2012) (0)
Aldosterone excretion correlated with body weight in men but not women with resistant hypertension (2004) (0)
Similar response to spironolactone in Whites and African-American patients with resistant hypertension (2008) (0)
High dietary sodium blunts effects of mineralocorticoid receptor antagonism on left ventricular hypertrophy regression in patients with resistant hypertension (2016) (0)
Levels of 24-h urinary sodium predict blood pressure response to spironolactone in uncontrolled resistant hypertensive patients independent of aldosterone status (2015) (0)
Abstract 11968: Nocturnal Blood Pressure in Young Adults and Cognitive Function in Midlife: The CARDIA Study (2014) (0)
Similar prevalence of hyperaldosteronism in African American and White subjects with resistant hypertension (2008) (0)
Abstract 17036: Uncontrolled Apparent Treatment Resistant Hypertension is Associated With Increased Hospitalization and Increased Total Hospital Reimbursements (2015) (0)
Abstract 327: The Choice of Diuretic is Important in the Treatment of Resistant Hypertension (2014) (0)
Race and muscle sympathetic nerve reactivity to mental and physical stress. (1995) (0)
Non-Dipping Pattern and Endothelial Dysfunction Are Associated with Uncontrolled Blood Pressure in Resistant Hypertension (2011) (0)
NATIONAL PATTERNS IN INTENSITY OF OUTPATIENT CARE FOR APPARENT TREATMENT RESISTANT HYPERTENSION (2015) (0)
Abstract P149: Maintenance of Optimal Health Behaviors Over 25 Years and Cumulative Blood Pressure Burden: Prospective Data From the Coronary Artery Risk Development in Young Adults Study (2017) (0)
Spironolactone as add-on therapy to chlorthalidone improves endothelial function, arterial stiffness and insulin resistance in European and African American patients with essential hypertension – A double-blind placebo-controlled randomized study (2014) (0)
Abstract MP46: Association of healthy lifestyle factors with all-cause mortality and incident cardiovascular events among individuals with apparent treatment resistant hypertension: the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study (2014) (0)
Adverse cardiac remodeling is absent in patients with true controlled resistant hypertension. (2023) (0)
Mineralocorticoid receptor blocker usage among sleep apnea subjects with resistant hypertension (2016) (0)
Response to should more significance be granted to medication response to antihypertensives in patients with resistant hypertension? (2014) (0)
RESERPINE SUBSTANTIALLY LOWERS BLOOD PRESSURE IN PATIENTS WITH REFRACTORY HYPERTENSION, A PHENOTYPE OF ANTIHYPERTENSIVE TREATMENT FAILURE (2020) (0)
Abstract P234: Obstructive Sleep Apnea is More Common in Patients With Masked Uncontrolled Hypertension (2018) (0)
Hypertension: Initial evaluation (1996) (0)
Abstract P209: Antihypertensive Medication Non-Adherence is Common in Patients With Suspected Refractory Hypertension (2018) (0)
Hypertension and hyperaldosteronism: a common association (2007) (0)
176 ALDOSTERONE EXCESS IS ASSOCIATED WITH TRUE TREATMENT RESISTANCE AS INDICATED BY SUSTAINED AMBULATORY BLOOD PRESSURE LEVELS AND LESS WHITE-COAT EFFECT. (2007) (0)
Assessment of left atrial volume in resistant hypertension by cardiac magnetic resonance imaging (2006) (0)
CARDIOVASCULAR OUTCOMES AND ALL-CAUSE MORTALITY ASSOCIATED WITH APPARENT TREATMENT-RESISTANT HYPERTENSION APPLYING THE 2017 ACC/AHA GUIDELINE (2021) (0)
Abstract 17118: Isolated Diastolic Hypotension Without Systolic Hypotension or Hypertension is an Independent Risk Factor for Incident Heart Failure Among Community-Dwelling Older Adults (2011) (0)
Abstract P174: Incidence of Hyponatremia on Spironolactone in Patients With a Prior Episode of Chlorthalidone-Induce Hyponatremia (2019) (0)
371 SLEEP APNEA AND HYPERALDOSTERONISM IN PATIENTS WITH RESISTANT HYPERTENSION (2005) (0)
Editorial comment: change in leadership (2015) (0)
NOVEL 24-HOUR BLOOD PRESSURE PROFILE IN PATIENTS WITH RESISTANT HYPERTENSION (2019) (0)
Aldosterone induces intracardiac volume overload in patients with resistant hypertension - spironolactone but not thiazide diuretics overcomes it (2008) (0)
Update From the Editors to Our Readers. (2017) (0)
E102: Enhanced dihydropyridine-induced increase in sympathetic activity is secondary to increases in minimum nerve activity (1998) (0)
Abstract P187: Incidence and Predictors of Diuretic-Induced Hyponatremia (2019) (0)
P-626: Aldosterone excretion is related to severity of sleep apnea in men and not in women with resistant hypertension (2005) (0)
High-salt diet and aldosterone induces vascular damage in patients with resistant hypertension (2008) (0)
Metabolic syndrome and insulin resistance in the trophy sub-study: contrasting views in high normal blood pressure (2004) (0)
Chapter 36 – Resistant Hypertension (2007) (0)
The National Health and Nutrition Examination Survey III: How Are We Doing with Blood Pressure Control? (2000) (0)
Dietary salt restriction in patients with resistant hypertension controls blood pressure and improves vascular function (2008) (0)
Original Investigation Incident ESRD and Treatment-Resistant Hypertension: The Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study (2014) (0)
OS 33-02 IN PATIENTS WITH RESISTANT HYPERTENSION INCREASED 24-H URINARY CORTISOL LEVEL PREDICT INCREASED BODY MASS INDEX. (2016) (0)
Calcium antagonists: antihypertensive and vascular considerations (1995) (0)
The ACC/AHA and ESC/ESH Hypertension Guidelines: Contrasting Versions of Idiosyncratic Excellence. (2019) (0)
Spironolactone improves aldosterone related obstructive sleep apnea in subjects with resistant hypertension (2008) (0)
25-Hydroxyvitamin D may contribute to differences in arterial stiffness and endothelial function in healthy African Americans compared to European Americans (2011) (0)
Aldosterone, Salt, and Vascular Injury: Lessons from Rodent Models with (2005) (0)
ANTIHYPERTENSIVE TREATMENT FAILURE NOT ATTRIBUTABLE TO PERSISTENT INTRAVASCULAR FLUID RETENTION AS DETERMINED BY MRI-MEASURED INTRACARDIAC VOLUMES (2017) (0)
ADHERENCE DECREASES WITH HIGHER NUMBER OF MEDICATIONS IN CONTROLLED HYPERTENSIVE PATIENTS, CONTROLLED RESISTANT PATIENTS HAVE LOWER ADHERENCE THAN CONTROLLED NON-RESISTANT PATIENTS (2021) (0)
Abstract P326: Apparent Treatment Resistant Hypertension and Risk for Stroke, Coronary Heart Disease and All-cause Mortality (2013) (0)
ELUCIDATION OF OBSTRUCTIVE SLEEP APNEA RELATED BLOOD PRESSURE RESPONSE USING CONTINUOUS BEAT TO BEAT BLOOD PRESSURE MONITORING (2021) (0)
LEFT VENTRICULAR MASS AND DIASTOLIC FUNCTION ARE SIMILAR IN PATIENTS WITH CONTROLLED RESISTANT AND CONTROLLED NON-RESISTANT HYPERTENSION (2019) (0)
Special Lecture (2005) (0)
Abstract 15037: Hyperreninemic Aldosteronism in Caucasian and African-American Patients With Apparent Resistant Hypertension (2015) (0)
Comparison of cardiovascular, renal, and mortality outcomes in refractory, resistant, and general hypertension (HTN) populations (2014) (0)
Prevalence of white coat and masked hypertension in refractory and controlled resistant hypertensive patients (2015) (0)
Abstract 104: Amplification of Systolic Blood Pressure and Pulse Pressure is Higher in Resistant Hypertensive Patients Irrespective of Blood Pressure Control (2019) (0)
E098 Mibefradil, a selective T-Type CA2 channel blocker, compared to nifedipine gits and enalapril in the treatment of hypertension (1998) (0)
Increased 24-h urinary aldosterone and cortisol levels with increasing body mass index in patients with resistant hypertension (2016) (0)
Evaluation of an endotoxin-mediated rodent model of preeclampsia (1999) (0)
Aldosterone excess increases left and right heart volumes in patients with resistant hypertension: Spironolactone but not thiazide diuretics overcome it (2008) (0)
DIASTOLIC FUNCTION: MEASURING LEFT VENTRICULAR UNTWISTING AS A DAMPED HARMONIC OSCILLATOR (2021) (0)
A014: Nicardipine has direct sympatho-excitatory effect (2000) (0)
785 RESISTANT AND REFRACTORY HYPERTENSION: DIVERGING PHENOTYPES? (2012) (0)
3 ALDOSTERONE EXCRETION IS NOT RELATED TO SLEEP DISRUPTION IN SUBJECTS WITH RESISTANT HYPERTENSION. (2006) (0)
Clinical trials report. Metabolic effects of carvedilol versus metoprolol in patients with type 2 diabetes mellitus and hypertension. (2005) (0)
Team Science: American Heart Association's Hypertension Strategically Focused Research Network Experience. (2021) (0)
ANTIHYPERTENSIVE EFFICACY OF AMLODIPINE/VALSARTAN/HYDROCHLOROTHIAZIDE TRIPLE COMBINATION IN PATIENTS WITH OBESITY: A SUBGROUP ANALYSIS: PP.34.421 (2010) (0)
The Year in Clinical Hypertension From Other Pages. (2019) (0)
Editorial introducing David as EiC (2012) (0)
Muscle sympathetic nerve activity response to chronic felodipine therapy. (1996) (0)
Treatment of resistant hyperte nsion (2010) (0)
Abstract P348: Association Between Sleep Apnea and Blood Pressure Control Among African-Americans, the Jackson Heart Study (2018) (0)
Response to Comment on optimal treatment for resistant hypertension: the missing data on pulse wave velocity. (2014) (0)
F3 Acute administration of nicardipine induces greater reflexive increase in sympthetic nerve activity than enalaprilat (1997) (0)
Abstract 19999: A Drop in Admission Serum Creatinine is Prognostically Similar to a Rise in Admission Serum Creatinine in Hospitalized Medicare Beneficiaries with Heart Failure: Impact on 30-Day All-Cause Readmission (2014) (0)
Aldosterone and Metabolic Dysfunction An Unresolved (2009) (0)
Dietary Sodium and Aldosterone Levels Are Related to Severity of Obstructive Sleep Apnea in Patients with Resistant Hypertension (2011) (0)
Web Exclusive. Annals On Call - Primary Aldosteronism: How Often Are We Missing It? (2018) (0)
P-324: Low prevalcne of white-coat hypertension in subjects with resistant hypertension and hyperaldosteronism (2004) (0)
Abstract P273: Association Between 24-hr Urinary Cortisol and Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension (2017) (0)
P-453: Weight loss with orlistat reduces cardiovascular risk in obese individuals with treated but insufficiently controlled hypertension (2002) (0)
Abstract P317: Nocturnal Blood Pressure Variability is associated with hs-CRP in Hypertensive Patients (2018) (0)
Abstract 19898: Heightened Sympathetic Activity Related to Masked Uncontrolled Hypertension in Treated Hypertensive Patients (2016) (0)
Robert M. Carey, Hypertension and Hormone Mechanisms (2008) (0)
The optimal management of patients with resistant hypertension due to aldosterone excess (2010) (0)
PO-09: SPIRONOLACTONE AS ADD-ON THERAPY TO CHLORTHALIDONE IMPROVES ENDOTHELIAL FUNCTION, ARTERIAL STIFFNESS AND INSULIN RESISTANCE IN EUROPEAN AND AFRICAN AMERICAN PATIENTS WITH ESSENTIAL HYPERTENSION – A DOUBLE-BLIND PLACEBO- CONTROLLED RANDOMIZED S (0)
Multiple linear regression analyses of variables modifying VDBP concentrations. (2014) (0)
Obstructive Sleep Apnea and Sodium Intake: Response (2013) (0)
Higher Ambulatory Blood Pressure and Less White-Coat Effect in Subjects with Hyperaldosteronism and Resistant Hypertension: 79 (2006) (0)
Rapid Communication Diurnal Blood Pressure Variation and Dietary Salt in Spontaneously Hypertensive Rats (2005) (0)
Abstract P163: Masked Uncontrolled Hypertension in Treated Hypertensive Patients Have Heightened Out-Of-Clinic Aldosterone Levels (2019) (0)
P-523: Leptin is associated with insulin resistance and impaired small artery distensibility in subjects with high normal blood pressure (2002) (0)
HIGH PREVALENCE OF INFLAMMATORY DISORDERS IN PATIENTS WITH REFRACTORY HYPERTENSION (2019) (0)
Resistant hypertension characterized by hyperaldosteronism and refractory intravascular volume expansion (2007) (0)
Abstract 15486: Spironolactone Reduces Severity of Obstructive Sleep Apnea in Resistant Hypertension (2012) (0)
Response to “Effective” Plasma Renin Activity: A Derived Measure for Assessing Residual Plasma Renin Activity in Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers (2010) (0)
Chapter 59 – Resistant Hypertension (2005) (0)
PS 14-14 24-HOUR URINARY SODIUM PREDICTS LEFT VENTRICULAR HYPERTROPHY REGRESSION TO SPIRONOLACTONE IN PATIENTS WITH RESISTANT HYPERTENSION (2016) (0)
Abstract P076: Racial Differences in Maintaining Optimal Healthy Lifestyles Until 50 Years of Age: Prospective Data From the Coronary Artery Risk Development in Young Adults Study (2017) (0)
High dietary salt worsens urinary protein excretion in patients with aldosterone excess and resistant hypertension (2007) (0)
Abstract P160: Non-invasive Method to Assess Human Circadian Rhythms (2016) (0)
ALDOSTERONE AND CORTISOL: IS THERE A COMMON STIMULUS IN SUBJECTS WITH RESISTANT HYPERTENSION?: 168 (2007) (0)
Comparative outcomes in sleep apnea among resistant and non-resistant hypertension (2015) (0)
CHAPTER 28 – Hypertensive Emergencies (2010) (0)
MASKED UNCONTROLLED HYPERTENSION IN TREATED HYPERTENSIVE PATIENTS IS NOT RELATED TO ANXIETY COMPARED TO TRUE CONTROLLED HYPERTENSION (2019) (0)
Research Article Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement (2016) (0)
ROSUVASTATIN IMPROVES ENDOTHELIAL FUNCTION THROUGH FAVORABLE EFFECTS ON NO AND 02- BALANCE.: OP 122 (2004) (0)
OS 24-04 A PILOT STUDY ASSESSING THE FEASIBILITY OF VASCULAR FUNCTION IN LOW SOCIOECONOMIC STATUS PRESCHOOL CHILDREN (2016) (0)
Elucidation of obstructive sleep apnoea related blood pressure surge using a novel continuous beat-to-beat blood pressure monitoring system (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David A. Calhoun?

David A. Calhoun is affiliated with the following schools: